Suraj Kalia
Stock Analyst at Oppenheimer
(3.72)
# 737
Out of 4,970 analysts
82
Total ratings
47.14%
Success rate
9.97%
Average return
Main Sectors:
Stocks Rated by Suraj Kalia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRCT PROCEPT BioRobotics | Upgrades: Outperform | $60 | $38.34 | +56.49% | 2 | Sep 2, 2025 | |
| PLSE Pulse Biosciences | Initiates: Outperform | $22 | $15.23 | +44.45% | 1 | Jul 7, 2025 | |
| TMDX TransMedics Group | Maintains: Outperform | $130 → $150 | $104.05 | +44.16% | 11 | Jun 17, 2025 | |
| ATRC AtriCure | Maintains: Outperform | $36 → $45 | $35.66 | +26.19% | 7 | Feb 13, 2025 | |
| VREX Varex Imaging | Maintains: Outperform | $30 → $23 | $11.60 | +98.28% | 6 | Feb 7, 2025 | |
| IRTC iRhythm Technologies | Maintains: Outperform | $105 → $120 | $182.17 | -34.13% | 5 | Jan 8, 2025 | |
| AORT Artivion | Maintains: Outperform | $30 → $32 | $44.03 | -27.32% | 3 | Nov 8, 2024 | |
| LMAT LeMaitre Vascular | Reiterates: Outperform | $90 → $93 | $97.07 | -4.19% | 2 | Nov 1, 2024 | |
| ABT Abbott Laboratories | Initiates: Outperform | $130 | $132.81 | -2.12% | 1 | Oct 8, 2024 | |
| TLSI TriSalus Life Sciences | Initiates: Outperform | $10 | $5.15 | +94.17% | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 | $80.96 | +11.17% | 5 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $13 | $5.70 | +128.07% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $135 | $106.60 | +26.64% | 1 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $273.81 | - | 6 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $13.42 | +123.55% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $320 → $200 | $2.17 | +9,116.59% | 1 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $97 | $74.12 | +30.87% | 1 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $28 | $25.87 | +8.23% | 4 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $4.5 | $1.53 | +194.12% | 1 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $1.46 | +995.89% | 1 | Sep 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $454.52 | - | 3 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $660 | $2.27 | +28,974.89% | 2 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $86.32 | - | 2 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $3.72 | - | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $100 | $23.58 | +324.09% | 1 | Jun 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $80.76 | - | 5 | Sep 12, 2018 |
PROCEPT BioRobotics
Sep 2, 2025
Upgrades: Outperform
Price Target: $60
Current: $38.34
Upside: +56.49%
Pulse Biosciences
Jul 7, 2025
Initiates: Outperform
Price Target: $22
Current: $15.23
Upside: +44.45%
TransMedics Group
Jun 17, 2025
Maintains: Outperform
Price Target: $130 → $150
Current: $104.05
Upside: +44.16%
AtriCure
Feb 13, 2025
Maintains: Outperform
Price Target: $36 → $45
Current: $35.66
Upside: +26.19%
Varex Imaging
Feb 7, 2025
Maintains: Outperform
Price Target: $30 → $23
Current: $11.60
Upside: +98.28%
iRhythm Technologies
Jan 8, 2025
Maintains: Outperform
Price Target: $105 → $120
Current: $182.17
Upside: -34.13%
Artivion
Nov 8, 2024
Maintains: Outperform
Price Target: $30 → $32
Current: $44.03
Upside: -27.32%
LeMaitre Vascular
Nov 1, 2024
Reiterates: Outperform
Price Target: $90 → $93
Current: $97.07
Upside: -4.19%
Abbott Laboratories
Oct 8, 2024
Initiates: Outperform
Price Target: $130
Current: $132.81
Upside: -2.12%
TriSalus Life Sciences
Sep 16, 2024
Initiates: Outperform
Price Target: $10
Current: $5.15
Upside: +94.17%
Sep 12, 2024
Maintains: Outperform
Price Target: $90
Current: $80.96
Upside: +11.17%
Aug 7, 2024
Maintains: Outperform
Price Target: $15 → $13
Current: $5.70
Upside: +128.07%
Jul 16, 2024
Initiates: Outperform
Price Target: $135
Current: $106.60
Upside: +26.64%
Jun 25, 2024
Downgrades: Perform
Price Target: n/a
Current: $273.81
Upside: -
Aug 8, 2023
Maintains: Outperform
Price Target: $24 → $30
Current: $13.42
Upside: +123.55%
Jun 23, 2023
Maintains: Outperform
Price Target: $320 → $200
Current: $2.17
Upside: +9,116.59%
May 16, 2023
Initiates: Outperform
Price Target: $97
Current: $74.12
Upside: +30.87%
Mar 6, 2023
Reiterates: Outperform
Price Target: $28
Current: $25.87
Upside: +8.23%
Nov 29, 2022
Initiates: Outperform
Price Target: $4.5
Current: $1.53
Upside: +194.12%
Sep 24, 2021
Initiates: Outperform
Price Target: $16
Current: $1.46
Upside: +995.89%
Apr 21, 2021
Upgrades: Perform
Price Target: n/a
Current: $454.52
Upside: -
Nov 17, 2020
Upgrades: Outperform
Price Target: $660
Current: $2.27
Upside: +28,974.89%
Nov 3, 2020
Upgrades: Perform
Price Target: n/a
Current: $86.32
Upside: -
Sep 15, 2020
Initiates: Perform
Price Target: n/a
Current: $3.72
Upside: -
Jun 24, 2020
Initiates: Outperform
Price Target: $100
Current: $23.58
Upside: +324.09%
Sep 12, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $80.76
Upside: -